Citation Impact
Citing Papers
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
2008 Standout
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis
2016
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
2008 Standout
Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo
2018 Standout
Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies
2005
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
2005
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Effect of neramexane on ethanol dependence and reinforcement
2004
Smarter drugs emerging in pancreatic cancer therapy
2014
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
2010 Standout
Molecular imaging in drug development
2008 Standout
Enhanced T-Cell Responses to Glioma Cells Coated With the Anti-EGF Receptor Antibody and Targeted to Activating FcγRs on Human Dendritic Cells
2008 StandoutNobel
NMDA receptors in clinical neurology: excitatory times ahead
2008
Pathological roles of MAPK signaling pathways in human diseases
2010 Standout
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Epidermal Growth Factor Receptor Targeting in Cancer
2006
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Using imaging biomarkers to accelerate drug development and clinical trials
2005
REVIEW ON CPP: Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade
2007 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
The molecular biology of head and neck cancer
2010 Standout
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
Monoclonal antibody therapy of cancer
2005
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Metastatic Colorectal Cancer
2007
Review of the Apoptosis Pathways in Pancreatic Cancer and the Anti‐apoptotic Effects of the Novel Sea Cucumber Compound, Frondoside A
2008
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Novel targets in gastric and esophageal cancer
2006
Reactive oxygen species in cancer
2010 Standout
Cetuximab Therapy and Symptomatic Hypomagnesemia
2005
Monoclonal antibodies for brain tumour treatment
2004
Integration of EGFR inhibitors with radiochemotherapy
2006
Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer
2007
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
2009 Standout
Natural compounds for cancer treatment and prevention
2009 Standout
Emerging drugs for non-small-cell lung cancer
2007
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Transient Receptor Potential Cation Channels in Disease
2007 Standout
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009 Standout
Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors
2008
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Epidermal growth factor receptor (EGFR) signaling in cancer
2005 Standout
ROS signalling in the biology of cancer
2017 Standout
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
2007 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Does Induction Chemotherapy Have a Role in the Management of Locoregionally Advanced Squamous Cell Head and Neck Cancer?
2006
Magnesium in Man: Implications for Health and Disease
2014 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
2005
Luteolin Induces Apoptosis in Oral Squamous Cancer Cells
2008
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
High-Value Components and Bioactives from Sea Cucumbers for Functional Foods—A Review
2011 Standout
Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer
2006
Antibody−Dendrimer Conjugates: The Number, Not the Size of the Dendrimers, Determines the Immunoreactivity
2008
Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice
2017
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
Mice with a human touch
2007
Cancer Genome Landscapes
2013 StandoutScience
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Flavonoids in Cancer and Apoptosis
2018 Standout
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Applications of Fluorine in Medicinal Chemistry
2015 Standout
Somatic Mutations of Epidermal Growth Factor Receptor in Colorectal Carcinoma
2005
Review. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization.
2007
Positron Emission Tomography in CNS Drug Discovery and Drug Monitoring
2014
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
2005
Works of J. Tillner being referenced
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
2006
EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study
2004
Amino-Alkyl-Cyclohexanes as a Novel Class of Uncompetitive NMDA Receptor Antagonists
2002
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
2006
Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD)
2004
A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies
2005
Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD)
2004
Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes
2014
Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer
2004
Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor
2003